Pfizer licenses three in vivo CAR-T programs from Starna
Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash
Pfizer signed an exclusive licensing deal with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. Pfizer pays $330 million upfront plus up to $2.3 billion in milestones and royalties on net sales. The deal expands Pfizer's Inflammation & Immunology pipeline and uses its RNA delivery expertise.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.